

Special Issue

Diagnosis, Prognosis and Management of Hematologic Malignancies

Message from the Guest Editors

Hematologic malignancies are cancers affecting blood, bone marrow and lymphonodes. They include leukemias, myeloproliferative and lymphoproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), lymphoma and multiple myeloma (MM), respectively. Acute myeloid leukemia (AML) is a clonal hematopoietic disorder characterized by a block in myeloid differentiation. Despite an improved understanding of the molecular and phenotypic characteristics of AML, there is a poor or moderate anti-leukemic response or relapse following short remission. Therefore, the identification of therapeutic targets expressed on leukemia stem cells might improve the potential clinical of AML treatment as well as predict patient outcome. Myeloproliferative neoplasms (MPNs) are malignancies caused by somatic driver mutations, such as JAK2V617F. MPNs have critical outcomes, including progression to MF or blast phase disease (MPN-BP), thrombosis and death.

Guest Editors

Prof. Dr. Rossella Cacciola

Dr. Emma C. Cacciola

Dr. Alessandra Romano

Dr. Alessandro Allegra

Deadline for manuscript submissions

31 October 2025



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/194446

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).